Is it Finally Time to Buy Medical Properties Trust?
Medical Properties Trust (NYSE:MPW) is a REIT that focuses on…
Sell
38
CERS Quote, Financials, Valuation and Earnings
Last price:
$1.42
Seasonality move
:
0.7%
Day range:
$1.42 - $1.47
52-week range:
$1.38 - $2.54
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.47x
P/B ratio:
4.77x
Volume:
1.1M
Avg. volume:
1.5M
1-year change:
-19.55%
Market cap:
$267.5M
Revenue:
$180.3M
EPS (TTM):
-$0.11
Analysts' Opinion
-
Consensus RatingCerus has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.25, Cerus has an estimated upside of 195.14% from its current price of $1.44.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $1.44.
Fair Value
-
According to the consensus of 5 analysts, Cerus has 195.14% upside to fair value with a price target of $4.25 per share.
CERS vs. S&P 500
-
Over the past 5 trading days, Cerus has underperformed the S&P 500 by -6.31% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Cerus does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Cerus has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Cerus reported revenues of $50.8M.
Earnings Growth
-
Cerus has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Cerus reported earnings per share of -$0.01.
Enterprise value:
272M
EV / Invested capital:
1.93x
Price / LTM sales:
1.47x
EV / EBIT:
--
EV / Revenue:
1.51x
PEG ratio (5yr expected):
--
EV / Free cash flow:
31.92x
Price / Operating cash flow:
31.19x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$99.5M
Return On Assets:
-10.86%
Net Income Margin (TTM):
-11.6%
Return On Equity:
-39.46%
Return On Invested Capital:
-15.36%
Operating Margin:
-2.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $162M | $156.4M | $180.3M | $46.8M | $50.8M | |
| Gross Profit | $87.1M | $86.4M | $99.5M | $26M | $27.4M | |
| Operating Income | -$34.1M | -$26.3M | -$14.2M | $976K | -$1.4M | |
| EBITDA | -$33.5M | -$26.3M | -$10M | $1.6M | -$66K | |
| Diluted EPS | -$0.25 | -$0.21 | -$0.11 | -$0.01 | -$0.01 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $183.4M | $187.1M | $170.1M | $144.4M | $152M | |
| Total Assets | $221.4M | $237.5M | $218.1M | $197.7M | $200.9M | |
| Current Liabilities | $60M | $78.6M | $117.1M | $67.5M | $63.6M | |
| Total Liabilities | $117.6M | $151.9M | $149.5M | $144.3M | $144M | |
| Total Equity | $103.8M | $85.6M | $68.6M | $53.4M | $56.9M | |
| Total Debt | $48.1M | $69.4M | $69.8M | $79.8M | $84.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$25.6M | -$43.2M | $11.4M | -$15.2M | $4.9M | |
| Cash From Investing | $8.5M | $8.6M | -$8.1M | $8.2M | -$7.3M | |
| Cash From Financing | $4.2M | $10.7M | $5M | $1.2M | $746K | |
| Free Cash Flow | -$27.6M | -$47.8M | $8.5M | -$15.2M | $4M | |
CERS
Sector
Market Cap
$267.5M
$36.5M
Price % of 52-Week High
56.69%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-19.55%
-39.9%
Beta (5-Year)
1.556
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.49
200-day SMA
Sell
Level
$1.84
Bollinger Bands (100)
Sell
Level
1.55 - 1.85
Chaikin Money Flow
Sell
Level
-133.2M
20-day SMA
Sell
Level
$1.51
Relative Strength Index (RSI14)
Sell
Level
40.02
ADX Line
Sell
Level
16.52
Williams %R
Neutral
Level
-71.4286
50-day SMA
Sell
Level
$1.69
MACD (12, 26)
Sell
Level
-0.06
25-day Aroon Oscillator
Sell
Level
-68
On Balance Volume
Neutral
Level
166.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-5.0026)
Sell
CA Score
(Annual)
Level (-1.4213)
Buy
Beneish M-Score
(Annual)
Level (-3.3229)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (2.9302)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.
Stock Forecast FAQ
In the current month, CERS has received 4 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CERS average analyst price target in the past 3 months is $4.25.
-
Where Will Cerus Stock Be In 1 Year?
According to analysts, the consensus estimate is that Cerus share price will rise to $4.25 per share over the next 12 months.
-
What Do Analysts Say About Cerus?
Analysts are divided on their view about Cerus share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Cerus is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Cerus's Price Target?
The price target for Cerus over the next 1-year time period is forecast to be $4.25 according to 5 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CERS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Cerus is a Buy. 4 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CERS?
You can purchase shares of Cerus via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Cerus shares.
-
What Is The Cerus Share Price Today?
Cerus was last trading at $1.42 per share. This represents the most recent stock quote for Cerus. Yesterday, Cerus closed at $1.44 per share.
-
How To Buy Cerus Stock Online?
In order to purchase Cerus stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Signet Jewelers Stock Go Up So Much?
Signet Jewelers (NYSE:SIG) is the largest diamond retailer in the…
Why Did HealthEquity Stock Fall So Much?
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
69
CNXC alert for Mar 28
Concentrix [CNXC] is down 12.39% over the past day.
Buy
74
SLNO alert for Mar 28
Soleno Therapeutics [SLNO] is up 6.8% over the past day.
Buy
51
CAR alert for Mar 28
Avis Budget Group [CAR] is up 0.71% over the past day.
